Financhill
Back

Plus Therapeutics Quote, Financials, Valuation and Earnings

The Mysterious VC Firm Behind Nvidia's Secret Weapon

Details Here!
Sell
35

PSTV
Plus Therapeutics

Last Price:
1.31
Seasonality Move:
6.45%

7 Day Trial

ALL ACCESS PASS

$ 7

Yours Free! Top SIX AI Dividend Stocks Right Now

NO CREDIT CARD REQUIRED!

Plus Therapeutics Price Quote

$1.31
-0.05 (-3.68%)
(Updated: November 6, 2024 at 10:20 AM ET)

Plus Therapeutics Key Stats

Sell
35
Plus Therapeutics (PSTV) is a Sell

Day range:
$1.33 - $1.45
52-week range:
$1.15 - $2.78
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
1.24
P/B ratio:
0%

Volume:
19.4K
Avg. volume:
61.3K
1-year change:
-15%
Market cap:
$8M
Revenue:
$0
EPS:
$-3.16

How Much Does Plus Therapeutics Make?

Data Unavailable

Is Plus Therapeutics Growing As A Company?

Data Unavailable

Plus Therapeutics Stock Price Performance

What Is Plus Therapeutics 52-Week High & Low?

Plus Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Plus Therapeutics?

  • How Much Debt Does Plus Therapeutics Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Plus Therapeutics Have?
    Cash and short term investments quarterly total is $8.4M
  • What Is Plus Therapeutics’s Book Value Per Share?
    Book value per share is -1.34

Is Plus Therapeutics Cash Flow Positive?

  • What Is PSTV Cash Flow From Operations?
    Cash flow from operations (TTM) is -$9.9M
  • What Is Plus Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $8.2M
  • What Is Plus Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$4.2M

Plus Therapeutics Return On Invested Capital

Data Unavailable

Plus Therapeutics Earnings Date & Stock Price

Plus Therapeutics Competitors

  • Who Are Plus Therapeutics's Competitors?
    Below is a list of companies who compete with Plus Therapeutics or are related in some way:
    • Perspective Therapeutics Inc (CATX)
    • InfuSystems Holdings Inc (INFU)
    • Retractable Technologies Inc (RVP)
    • Catheter Precision Inc (VTAK)
    • Xtant Medical Holdings Inc (XTNT)

Plus Therapeutics Dividend Yield

Plus Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 15.09%
Revenue: 0% 14.54%

Analyst Recommendations

Buy Recommendations: 2
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 16.00
Upside from Last Price: 1076.47%

Major Shareholders

  • How many PSTV shares are owned by institutional investors?
    743.6K PSTV shares are owned by institutional investors
  • How many PSTV shares are owned by insiders?
    1.2M PSTV shares are owned by insiders